Legius syndrome

Last updated
Legius syndrome
Other namesNeurofibromatosis 1-like syndrome [1]
Autosomal dominant - en.svg
This condition is inherited in an autosomal dominant manner.
Symptoms café au lait spots; +/- learning disabilities [2]
Usual onsetat birth
Causes Mutations in the SPRED1 gene [3]
Diagnostic method Clinical findings, Genetic test [4]
Differential diagnosis neurofibromatosis type I
TreatmentPhysical therapy, Speech therapy [2] [1]
Prognosis good
Frequencyrare (estimated at 1:46,000-1:75,000) [2]

Legius syndrome (LS) is an autosomal dominant condition characterized by cafe au lait spots. [3] It was first described in 2007 and is often mistaken for neurofibromatosis type I. It is caused by mutations in the SPRED1 gene. [5] [6] It is also known as neurofibromatosis type 1-like syndrome. [1]

Contents

Symptoms and signs

larger cafe au lait spot on right forearm Cafe au lait fleck.jpg
larger café au lait spot on right forearm

Nearly all individuals with Legius syndrome show multiple café au lait spots on their skin. [7] Symptoms may include: [2]

Features common in neurofibromatosis – like Lisch nodules (iris hamartomas diagnosed on slit lamp exam), bone abnormalities, neurofibromas, optic pathway gliomas and malignant peripheral nerve sheath tumors – are absent in Legius syndrome. [1]

Cause

CHR 15 Human male karyotpe high resolution - Chromosome 15 cropped.png
CHR 15

Legius syndrome is a phakomatosis [8] and a RASopathy, a developmental syndrome due to germline mutations in genes. [7] [9] The condition is autosomal dominant in regards to inheritance and caused by mutations to the SPRED1 gene at chromosome 15, specifically 15q14 (or (GRCh38): 15:38,252,086-38,357,248). [10] [11] The gene in question demonstrates almost 100 mutations. [1]

Mechanism

A mutated SPRED1 protein adversely regulates Ras-MAPK signaling, which is a chain of proteins in a cell that sends signals from the surface of a cell to the nucleus which in turn causes the symptoms of this condition. [2] [12]

Diagnosis

Genetic testing is necessary to identify the syndrome. The DNA test is necessary sometimes, because symptoms may not be sufficient to definitely diagnose this condition. [4] [1] [13]

Differential diagnosis

The symptoms of Legius syndrome and neurofibromatosis type I are very similar; An important difference between Legius syndrome and neurofibromatosis type I is the absence of tumor growths Lisch nodules and neurofibromas which are common in neurofibromatosis type I. [2]

A genetic test is often the only way to make sure a person has Legius syndrome and not neurofibromatosis type I; the similarity of symptoms stem from the fact that the different genes affected in the two syndromes code for proteins that carry out a similar task in the same reaction pathway.[ medical citation needed ]

Treatment

Management of Legius syndrome is done via the following: [2] [1]

The prognosis of this condition is generally considered good with appropriate treatment.[ citation needed ]

See also

References

  1. 1 2 3 4 5 6 7 RESERVED, INSERM US14 -- ALL RIGHTS. "Orphanet: Legius syndrome". www.orpha.net. Retrieved 2017-06-01.{{cite web}}: CS1 maint: numeric names: authors list (link)
  2. 1 2 3 4 5 6 7 Stevenson, David; Viskochil, David; Mao, Rong (1993). "Legius Syndrome". GeneReviews. PMID   20945555 . Retrieved 1 June 2017.update 2015
  3. 1 2 "Legius syndrome", Genetics Home Reference, National Institutes of Health
  4. 1 2 "Legius syndrome | Genetic and Rare Diseases Information Center". rarediseases.info.nih.gov. Retrieved 2017-06-01.
  5. ↑ "SPRED1", Genetics Home Reference, National Institutes of Health
  6. ↑ "Legius Syndrome Often Mistaken for Neurofibromatosis Type 1", by Allison Gandley, November 18, 2009, Medscape
  7. 1 2 "OMIM Entry - # 611431 - LEGIUS SYNDROME". omim.org. Retrieved 2017-06-01.
  8. ↑ Rosser, Tena (February 2018). "Neurocutaneous Disorders". Continuum (Minneapolis, Minn.). 24 (1, Child Neurology): 96–129. doi:10.1212/CON.0000000000000562. ISSN   1538-6899. PMID   29432239. S2CID   4107835.
  9. ↑ Tidyman, William (2009). "The RASopathies: Developmental syndromes of Ras/MAPK pathway dysregulation". Current Opinion in Genetics & Development. 19 (3): 230–236. doi:10.1016/j.gde.2009.04.001. PMC   2743116 . PMID   19467855.
  10. ↑ "OMIM Entry - * 609291 - SPROUTY-RELATED EVH1 DOMAIN-CONTAINING PROTEIN 1; SPRED1". www.omim.org. Retrieved 2017-06-01.
  11. ↑ "Homo sapiens sprouty related EVH1 domain containing 1 (SPRED1), RefSeq - Nucleotide - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2017-06-01.
  12. ↑ Molina, Julian R.; Adjei, Alex A. (2006-01-01). "The Ras/Raf/MAPK Pathway". Journal of Thoracic Oncology. 1 (1): 7–9. doi: 10.1016/S1556-0864(15)31506-9 . PMID   17409820.
  13. ↑ "SPRED1 sprouty related EVH1 domain containing 1 - Gene - GTR - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2017-06-01.
  14. ↑ Storebø, Ole Jakob; Storm, Maja Rosenberg Overby; Pereira Ribeiro, Johanne; Skoog, Maria; Groth, Camilla; Callesen, Henriette E.; Schaug, Julie Perrine; Darling Rasmussen, Pernille; Huus, Christel-Mie L.; Zwi, Morris; Kirubakaran, Richard; Simonsen, Erik; Gluud, Christian (2023-03-27). "Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)". The Cochrane Database of Systematic Reviews. 2023 (3) CD009885. doi:10.1002/14651858.CD009885.pub3. ISSN   1469-493X. PMC   10042435 . PMID   36971690.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.